uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.899 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of Tendinopathy? | In the context of Tendinopathy, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%tendinopathy%" OR LOWER(efo_term) LIKE "%tendinopathy%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838136', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838187', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838204', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838221', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838255', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838272', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838289', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838306', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838170', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838102', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838068', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838051', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838238', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838153', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838119', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838085', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1934 | Q34 | What are the names of the genes that are targeted by the drug Azacitidine in the treatment of anemia? | In the context of anemia, the drug Azacitidine targets the gene DNA methyltransferase 1 and DNA methyltransferase 3 alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anemia%" OR LOWER(efo_term) LIKE "%anemia%") AND (LOWER(drugName) LIKE "%azacitidine%" OR LOWER(tradeNames_list) LIKE "%azacitidine%" OR LOWER(syns_list) LIKE "%azacitidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192044', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192106', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191982', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191920', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191918', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Refractory, with Excess of Blasts', 'efo_term': 'refractory anemia with excess blasts', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192104', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Refractory, with Excess of Blasts', 'efo_term': 'refractory anemia with excess blasts', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192042', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Refractory, with Excess of Blasts', 'efo_term': 'refractory anemia with excess blasts', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191980', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Refractory, with Excess of Blasts', 'efo_term': 'refractory anemia with excess blasts', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.553 | Q34 | What are the names of the genes that are targeted by the drug Fosphenytoin Sodium in the treatment of Seizure? | In the context of Seizure, the drug Fosphenytoin Sodium targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seizure%" OR LOWER(efo_term) LIKE "%seizure%") AND (LOWER(drugName) LIKE "%fosphenytoin sodium%" OR LOWER(tradeNames_list) LIKE "%fosphenytoin sodium%" OR LOWER(syns_list) LIKE "%fosphenytoin sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_632027', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632030', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632031', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632032', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632034', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632035', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632036', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632038', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632039', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632040', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632041', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632043', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632044', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632045', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632046', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632047', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632048', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632049', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632050', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632051', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632052', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632054', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632055', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632056', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632057', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632058', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632060', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632061', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632062', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632063', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632064', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632065', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632066', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632067', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632068', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632069', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632070', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632071', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_632072', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632073', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632074', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632075', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632076', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632077', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632078', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632079', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632080', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632081', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_632082', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632083', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632084', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632086', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632087', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632088', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632089', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632090', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632091', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632093', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632094', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632095', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632096', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632097', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632098', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632099', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632100', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632101', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632102', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632103', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632104', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632105', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632106', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632107', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632108', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632109', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632110', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632111', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_632112', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632113', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632114', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632115', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632116', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632117', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632118', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632119', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632120', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632121', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_632085', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_632053', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632037', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632029', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632025', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632023', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632022', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632092', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_632059', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632042', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632033', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632028', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632026', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632024', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_list': "['Cerebyx', 'Fosphenytoin sodium', 'Pro-epanutin', 'Sesquient']", 'syns_list': "['ACC-9653-010', 'ACC-9653-010 (SODIUM SALT)', 'CI 982', 'CI-982Fosphenytoin disodium salt', 'Fosphenytoin sodium']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1354 | Q34 | What are the names of the genes that are targeted by the drug Inclisiran Sodium in the treatment of familial hypercholesterolemia? | In the context of familial hypercholesterolemia, the drug Inclisiran Sodium targets the gene proprotein convertase subtilisin/kexin type 9. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial hypercholesterolemia%" OR LOWER(efo_term) LIKE "%familial hypercholesterolemia%") AND (LOWER(drugName) LIKE "%inclisiran sodium%" OR LOWER(tradeNames_list) LIKE "%inclisiran sodium%" OR LOWER(syns_list) LIKE "%inclisiran sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993750', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993756', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993758', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993760', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993764', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993766', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993768', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993772', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993774', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993776', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993770', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993746', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993742', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993740', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993754', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993762', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993752', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993748', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}, {'UUID': 'DrugTargetsIndication121923_text_993744', 'drugName': 'Inclisiran Sodium', 'tradeNames_list': "['Leqvio']", 'syns_list': "['Inclisiran sodium', 'Leqvio sodium']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'PCSK9', 'approvedName': 'proprotein convertase subtilisin/kexin type 9'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1527 | Q34 | What are the names of the genes that are targeted by the drug Aprepitant in the treatment of Nausea? | In the context of Nausea, the drug Aprepitant targets the gene tachykinin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea%" OR LOWER(efo_term) LIKE "%nausea%") AND (LOWER(drugName) LIKE "%aprepitant%" OR LOWER(tradeNames_list) LIKE "%aprepitant%" OR LOWER(syns_list) LIKE "%aprepitant%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072779', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072783', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072784', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072802', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072805', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072806', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072807', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072826', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072828', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072829', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072830', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072849', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072851', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072852', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072853', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072871', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072872', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072874', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072875', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072876', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072894', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072897', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072898', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072899', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072917', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072918', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072921', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072922', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072940', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072941', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072943', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072944', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072945', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072963', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072964', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072966', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072967', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072968', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072986', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072987', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072989', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072990', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072991', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073009', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073010', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073012', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073013', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073014', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073032', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073033', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073035', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073037', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073055', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073056', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073058', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073059', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073060', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073079', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073081', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073082', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073083', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073101', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073102', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073104', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073105', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073106', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073153', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073155', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073156', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073158', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073160', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073161', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073163', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073165', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073166', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073168', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073170', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073171', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073173', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073175', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073176', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073178', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073180', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073181', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073183', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073185', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073036', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072895', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072825', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072782', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072760', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072757', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072756', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073078', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072920', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072848', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072803', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072780', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072761', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072759', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1364 | Q34 | What are the names of the genes that are targeted by the drug Ibrutinib in the treatment of macroglobulinemia? | In the context of macroglobulinemia, the drug Ibrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%macroglobulinemia%" OR LOWER(efo_term) LIKE "%macroglobulinemia%") AND (LOWER(drugName) LIKE "%ibrutinib%" OR LOWER(tradeNames_list) LIKE "%ibrutinib%" OR LOWER(syns_list) LIKE "%ibrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_995128', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995219', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995220', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995265', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995311', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995312', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995357', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995403', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995404', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995449', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995450', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995496', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995541', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995542', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995587', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995588', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995633', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995634', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995679', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995680', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995725', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995771', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995772', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995817', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995818', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995863', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995909', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995910', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995955', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995956', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996001', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996002', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996047', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996048', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996093', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996094', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996139', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996140', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996185', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996186', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996231', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996232', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996277', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996278', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996323', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996324', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996369', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996370', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996415', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996416', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996461', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996507', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996508', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996553', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996554', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996599', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996600', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996646', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996691', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996692', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996737', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996738', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996783', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996784', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996829', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996830', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996875', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996876', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996921', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996922', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996967', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996968', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997013', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997014', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997059', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997060', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997105', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997106', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997151', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997152', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997197', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997198', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997243', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997244', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997289', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997290', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996462', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995726', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995358', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995174', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995082', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995036', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995035', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996645', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995864', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995495', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995266', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995173', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995127', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995081', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1166 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of cutaneous melanoma? | Trametinib has not been approved by the FDA as a treatment for cutaneous melanoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cutaneous melanoma%" OR LOWER(efo_term) LIKE "%cutaneous melanoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927764', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927785', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927792', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927799', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927813', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927820', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927827', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927841', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927848', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927855', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927862', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927876', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927883', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927890', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927897', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927904', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927911', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927918', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927925', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927932', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927939', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927953', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927960', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927967', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927974', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927981', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927995', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928002', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928009', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928016', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928023', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928030', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928037', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928044', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928051', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928058', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928065', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928072', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928079', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928086', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928093', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928100', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928107', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928114', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928121', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928128', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928135', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928142', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928149', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928156', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928163', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928177', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928184', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928191', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928198', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928205', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928212', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928226', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928233', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928240', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928247', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928254', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928261', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928268', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928275', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928282', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928289', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928296', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928303', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928310', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928317', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928324', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928331', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928338', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928345', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928352', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928359', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928366', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928373', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928380', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928387', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928394', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928401', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928408', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928415', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928422', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928170', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927946', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927834', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927778', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927750', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927736', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927729', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928219', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927988', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927869', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927806', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927771', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927757', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927743', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.562 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of Myalgia? | In the context of Myalgia, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myalgia%" OR LOWER(efo_term) LIKE "%myalgia%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_641571', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_643871', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_640881', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642031', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640651', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_638811', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641111', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642491', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_644216', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_643756', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637891', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640191', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642951', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643066', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_638121', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640536', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_643986', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_640421', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638926', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638581', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641226', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641456', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_643181', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_641686', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_640306', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639846', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642261', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637776', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642376', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638351', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642606', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_640766', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_638236', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640996', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642836', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_639041', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_643296', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_638006', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644331', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_639501', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640076', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_641916', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_639731', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_642146', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_639271', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639616', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638466', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639961', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639386', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_642721', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_644101', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_643641', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643411', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_641341', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_644446', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641801', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639156', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_643526', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644561', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_638696', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641202', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_638787', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639822', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_641892', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642007', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_639937', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639477', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_642237', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_638327', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638902', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_642352', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642467', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640167', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642697', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_639017', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_640282', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_642812', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642927', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_640397', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_643042', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642582', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643157', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637867', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638442', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639132', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640052', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640512', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_643272', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643387', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_640627', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642122', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_639247', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640742', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640857', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_638097', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639362', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640972', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641087', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_638557', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641317', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.141 | Q34 | What are the names of the genes that are targeted by the drug Osimertinib in the treatment of neoplasm? | In the context of neoplasm, the drug Osimertinib targets the gene epidermal growth factor receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%osimertinib%" OR LOWER(tradeNames_list) LIKE "%osimertinib%" OR LOWER(syns_list) LIKE "%osimertinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217195', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217291', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217231', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217219', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217328', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217376', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217364', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217280', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217183', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217388', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217316', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217279', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217304', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217315', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217207', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217340', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217375', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217220', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217267', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217303', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217268', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217255', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217292', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217208', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217327', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217256', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217184', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217363', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217244', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217232', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217387', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217243', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217196', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217339', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217352', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217351', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217361', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217374', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217350', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217217', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217218', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217301', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217181', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217289', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217182', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217385', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217314', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217326', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217229', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217302', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217337', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217241', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217193', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217290', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217253', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217242', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217194', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217349', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217230', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217265', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217266', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217325', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217254', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217373', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217362', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217313', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217205', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217386', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217338', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217206', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217277', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217278', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217252', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217264', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217228', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217204', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217348', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217276', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217216', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217360', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217180', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217288', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217300', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217372', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217312', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217324', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217384', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217336', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217240', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217192', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217234', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217330', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217186', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217162', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217246', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217150', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217164', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217166', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217258', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217198', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1718 | Q34 | What are the names of the genes that are targeted by the drug Ezetimibe in the treatment of familial hypercholesterolemia? | In the context of familial hypercholesterolemia, the drug Ezetimibe targets the gene NPC1 like intracellular cholesterol transporter 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial hypercholesterolemia%" OR LOWER(efo_term) LIKE "%familial hypercholesterolemia%") AND (LOWER(drugName) LIKE "%ezetimibe%" OR LOWER(tradeNames_list) LIKE "%ezetimibe%" OR LOWER(syns_list) LIKE "%ezetimibe%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097369', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097410', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097411', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097390', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097327', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097326', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097348', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'homozygous familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097389', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097368', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}, {'UUID': 'DrugTargetsIndication121923_text_1097347', 'drugName': 'Ezetimibe', 'tradeNames_list': "['Ezetimibe', 'Ezetrol', 'Zetia']", 'syns_list': "['Ezetimibe', 'MK0653', 'NSC-758923', 'SCH-58235', 'SCH58235']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'NPC1L1', 'approvedName': 'NPC1 like intracellular cholesterol transporter 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.535 | Q34 | What are the names of the genes that are targeted by the drug Carbinoxamine Maleate in the treatment of Rhinitis, Allergic, Perennial? | In the context of Rhinitis, Allergic, Perennial, the drug Carbinoxamine Maleate targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rhinitis, allergic, perennial%" OR LOWER(efo_term) LIKE "%rhinitis, allergic, perennial%") AND (LOWER(drugName) LIKE "%carbinoxamine maleate%" OR LOWER(tradeNames_list) LIKE "%carbinoxamine maleate%" OR LOWER(syns_list) LIKE "%carbinoxamine maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455853', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455859', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.226 | Q34 | What are the names of the genes that are targeted by the drug Betamethasone Dipropionate in the treatment of psoriasis? | In the context of psoriasis, the drug Betamethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis%" OR LOWER(efo_term) LIKE "%psoriasis%") AND (LOWER(drugName) LIKE "%betamethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%betamethasone dipropionate%" OR LOWER(syns_list) LIKE "%betamethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220861', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220881', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220885', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220893', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220905', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220909', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220873', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220849', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220837', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220833', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220897', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220869', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220857', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220845', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.728 | Q34 | What are the names of the genes that are targeted by the drug Dabrafenib Mesylate in the treatment of metastatic melanoma? | In the context of metastatic melanoma, the drug Dabrafenib Mesylate targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic melanoma%" OR LOWER(efo_term) LIKE "%metastatic melanoma%") AND (LOWER(drugName) LIKE "%dabrafenib mesylate%" OR LOWER(tradeNames_list) LIKE "%dabrafenib mesylate%" OR LOWER(syns_list) LIKE "%dabrafenib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752713', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752734', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752741', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752748', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752762', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752769', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752776', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752790', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752797', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752804', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752811', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752825', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752832', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752839', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752846', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752853', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752860', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752867', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752874', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752881', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752888', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752902', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752909', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752916', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752923', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752930', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752944', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752951', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752958', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752965', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752972', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752979', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752895', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752783', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752727', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752699', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752685', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752678', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752937', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752818', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752755', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752720', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752706', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752692', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.792 | Q34 | What are the names of the genes that are targeted by the drug Niraparib Tosylate in the treatment of Fallopian Tube Carcinoma? | In the context of Fallopian Tube Carcinoma, the drug Niraparib Tosylate targets the gene poly(ADP-ribose) polymerase 2 and poly(ADP-ribose) polymerase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fallopian tube carcinoma%" OR LOWER(efo_term) LIKE "%fallopian tube carcinoma%") AND (LOWER(drugName) LIKE "%niraparib tosylate%" OR LOWER(tradeNames_list) LIKE "%niraparib tosylate%" OR LOWER(syns_list) LIKE "%niraparib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823355', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823367', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823371', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823375', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823363', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823347', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823339', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823335', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823379', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823359', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823351', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823343', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1703 | Q34 | What are the names of the genes that are targeted by the drug Leuprolide Acetate in the treatment of prostate cancer? | In the context of prostate cancer, the drug Leuprolide Acetate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%leuprolide acetate%" OR LOWER(tradeNames_list) LIKE "%leuprolide acetate%" OR LOWER(syns_list) LIKE "%leuprolide acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097051', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097090', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097095', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097112', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097073', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097029', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097007', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097002', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097117', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097068', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097046', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097024', 'drugName': 'Leuprolide Acetate', 'tradeNames_list': "['Carcinil', 'Eligard', 'Eligard kit', 'Fensolvi kit', 'Leuprolide acetateLeuprorelin', 'Lupron', 'Lupron Depot Ped', 'Lupron depotLupron depot-ped', 'Lupron depot-ped kit', 'Lutrate depot kit', 'Viadur']", 'syns_list': "['A-43818', 'ABBOTT-43818', 'Carcinil', 'Enantone', 'Fensolvi', 'LeuplinLeuporelin acetate', 'Leuprolide acetate', 'Leuprolide monoacetateLeuprorelin acetate', 'Lucrin', 'Lupaneta', 'Lutrate depot', 'ProstapTAP-144', 'Tap-144-sr', 'Trenantone']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.971 | Q34 | What are the names of the genes that are targeted by the drug Tofacitinib Citrate in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Tofacitinib Citrate targets the gene Janus kinase 1, Janus kinase 3, tyrosine kinase 2 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%tofacitinib citrate%" OR LOWER(tradeNames_list) LIKE "%tofacitinib citrate%" OR LOWER(syns_list) LIKE "%tofacitinib citrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_848324', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848339', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848344', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848349', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848359', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848364', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848369', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848379', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848384', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848389', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848394', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848404', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848409', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848414', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848419', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848424', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848429', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848434', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848439', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848444', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848449', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848459', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848464', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848469', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848474', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848479', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848489', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848494', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848499', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848504', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848509', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848514', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848519', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848524', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848529', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848534', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848539', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848544', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848549', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848554', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848559', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848564', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848569', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848574', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848579', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848584', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848589', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848594', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848599', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848604', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848609', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848619', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848624', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848629', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848634', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848639', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848644', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848654', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848659', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848664', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848669', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848674', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848614', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848454', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848374', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848334', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848314', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848304', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848299', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848649', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848484', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848399', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848354', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848329', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848319', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848309', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.412 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone Butyrate in the treatment of atopic eczema? | In the context of atopic eczema, the drug Hydrocortisone Butyrate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%hydrocortisone butyrate%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone butyrate%" OR LOWER(syns_list) LIKE "%hydrocortisone butyrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243801', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_list': "['Hydrocortisone butyrate', 'Locoid', 'Locoid c', 'Locoid creloLocoid lipocream']", 'syns_list': "['Cortisol 17-butyrate', 'Hydrocortisone 17-butyrateHydrocortisone butyrate', 'Hydrocortisone-17-butyrate', 'NSC-758433']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243805', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_list': "['Hydrocortisone butyrate', 'Locoid', 'Locoid c', 'Locoid creloLocoid lipocream']", 'syns_list': "['Cortisol 17-butyrate', 'Hydrocortisone 17-butyrateHydrocortisone butyrate', 'Hydrocortisone-17-butyrate', 'NSC-758433']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.327 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of meningeal tuberculosis? | In the context of meningeal tuberculosis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%meningeal tuberculosis%" OR LOWER(efo_term) LIKE "%meningeal tuberculosis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227783', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228638', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228923', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229208', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229778', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230063', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230348', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230918', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231203', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231488', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231773', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232343', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230633', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228353', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227213', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226643', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226358', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232058', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229493', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228068', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227498', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226928', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1086 | Q34 | What are the names of the genes that are targeted by the drug Apalutamide in the treatment of metastatic prostate cancer? | In the context of metastatic prostate cancer, the drug Apalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic prostate cancer%" OR LOWER(efo_term) LIKE "%metastatic prostate cancer%") AND (LOWER(drugName) LIKE "%apalutamide%" OR LOWER(tradeNames_list) LIKE "%apalutamide%" OR LOWER(syns_list) LIKE "%apalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921896', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921926', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921936', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921946', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921916', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921876', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921856', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921846', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921956', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921906', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921886', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921866', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.301 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of systemic lupus erythematosus? | In the context of systemic lupus erythematosus, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%systemic lupus erythematosus%" OR LOWER(efo_term) LIKE "%systemic lupus erythematosus%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227756', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228611', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228896', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229181', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229751', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230036', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230321', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230891', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231176', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231461', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231746', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232316', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230606', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228326', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227186', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226616', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226331', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232031', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229466', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228041', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227471', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226901', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Erythematosus, Systemic', 'efo_term': 'systemic lupus erythematosus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1247 | Q34 | What are the names of the genes that are targeted by the drug Dutetrabenazine in the treatment of Huntington disease? | In the context of Huntington disease, the drug Dutetrabenazine targets the gene solute carrier family 18 member A2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%huntington disease%" OR LOWER(efo_term) LIKE "%huntington disease%") AND (LOWER(drugName) LIKE "%dutetrabenazine%" OR LOWER(tradeNames_list) LIKE "%dutetrabenazine%" OR LOWER(syns_list) LIKE "%dutetrabenazine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938617', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938635', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938641', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938647', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938659', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938665', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938671', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938683', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938689', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938695', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938701', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938713', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938719', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938725', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938731', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938737', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938743', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938749', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938755', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938761', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938767', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938779', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938785', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938791', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938797', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938803', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938815', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938821', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938827', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938833', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938839', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938845', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938851', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938857', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938863', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938869', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938875', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938881', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938887', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938893', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938899', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938905', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938911', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938917', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938923', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938773', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938677', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938629', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938605', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938593', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938587', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938809', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938707', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938653', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938623', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938611', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938599', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Huntington Disease', 'efo_term': 'Huntington disease', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1128 | Q34 | What are the names of the genes that are targeted by the drug Cobimetinib in the treatment of cancer? | In the context of cancer, the drug Cobimetinib targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%cobimetinib%" OR LOWER(tradeNames_list) LIKE "%cobimetinib%" OR LOWER(syns_list) LIKE "%cobimetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927539', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927608', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927447', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927700', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927263', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927470', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927585', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927240', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927677', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927355', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927217', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927309', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927654', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927424', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927378', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927493', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927401', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927332', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927723', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927516', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927562', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927631', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927286', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927194', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927694', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927280', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927211', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927395', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927532', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927693', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927256', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927509', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927187', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927647', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927487', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927486', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927625', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927349', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927348', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927233', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927417', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927234', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927671', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927670', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927418', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927302', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927441', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927648', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927510', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927303', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927533', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927188', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927257', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927394', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927602', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927601', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927279', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927325', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927555', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927463', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927326', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927717', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927440', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927371', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927624', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927556', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927464', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927716', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927372', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927578', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927579', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927210', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927180', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927226', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927272', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927364', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927571', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927387', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927594', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927295', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927617', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927410', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927640', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927663', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927433', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927686', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927709', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927548', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927203', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927249', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927318', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927456', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927479', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927341', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927502', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927525', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.26 | Q34 | What are the names of the genes that are targeted by the drug Brexpiprazole in the treatment of schizoaffective disorder? | In the context of schizoaffective disorder, the drug Brexpiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizoaffective disorder%" OR LOWER(efo_term) LIKE "%schizoaffective disorder%") AND (LOWER(drugName) LIKE "%brexpiprazole%" OR LOWER(tradeNames_list) LIKE "%brexpiprazole%" OR LOWER(syns_list) LIKE "%brexpiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155833', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155875', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155889', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155903', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155931', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155945', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155959', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155987', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156001', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156015', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156029', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156057', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156071', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156085', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156099', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156113', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156127', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156141', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156155', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156169', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156183', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156211', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156225', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156239', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156253', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156267', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156295', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156309', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156323', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156337', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156351', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156365', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156379', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156393', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156407', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156421', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156435', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156449', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156463', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156477', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156491', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156505', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156519', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156533', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156547', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156561', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156575', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156589', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156603', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156617', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156631', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156659', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156673', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156687', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156701', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156715', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156729', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156757', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156771', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156785', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156799', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156813', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156827', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156841', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156855', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156869', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156883', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156897', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156911', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156925', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156939', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156953', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156967', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156981', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156995', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157009', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157023', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157037', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157051', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157065', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157079', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157093', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157107', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157121', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157135', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157149', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156645', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156197', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155973', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155861', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155805', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155777', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155763', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156743', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156281', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156043', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155917', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155847', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155819', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155791', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1842 | Q34 | What are the names of the genes that are targeted by the drug Ivacaftor in the treatment of cystic fibrosis? | In the context of cystic fibrosis, the drug Ivacaftor targets the gene CF transmembrane conductance regulator. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cystic fibrosis%" OR LOWER(efo_term) LIKE "%cystic fibrosis%") AND (LOWER(drugName) LIKE "%ivacaftor%" OR LOWER(tradeNames_list) LIKE "%ivacaftor%" OR LOWER(syns_list) LIKE "%ivacaftor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103316', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103337', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103344', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103351', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103365', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103372', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103379', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103393', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103400', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103407', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103414', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103428', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103435', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103442', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103449', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103456', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103463', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103470', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103477', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103484', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103491', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103505', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103512', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103519', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103526', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103533', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103547', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103554', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103561', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103568', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103575', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103582', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103589', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103596', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103603', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103610', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103617', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103624', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103631', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103638', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103645', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103652', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103659', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103666', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103673', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103680', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103687', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103694', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103701', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103498', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103386', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103330', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103302', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103288', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103281', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103540', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103421', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103358', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103323', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103309', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103295', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cystic Fibrosis', 'efo_term': 'cystic fibrosis', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.719 | Q34 | What are the names of the genes that are targeted by the drug Vemurafenib in the treatment of melanoma? | In the context of melanoma, the drug Vemurafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%melanoma%" OR LOWER(efo_term) LIKE "%melanoma%") AND (LOWER(drugName) LIKE "%vemurafenib%" OR LOWER(tradeNames_list) LIKE "%vemurafenib%" OR LOWER(syns_list) LIKE "%vemurafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752119', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752140', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752158', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752160', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752179', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752181', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752182', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752202', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752203', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752221', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752223', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752200', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752139', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752116', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752097', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752095', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752224', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752161', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752137', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752118', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752098', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.973 | Q34 | What are the names of the genes that are targeted by the drug Abrocitinib in the treatment of Eczema? | In the context of Eczema, the drug Abrocitinib targets the gene Janus kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eczema%" OR LOWER(efo_term) LIKE "%eczema%") AND (LOWER(drugName) LIKE "%abrocitinib%" OR LOWER(tradeNames_list) LIKE "%abrocitinib%" OR LOWER(syns_list) LIKE "%abrocitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_848695', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848706', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848707', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848712', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848718', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848719', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848724', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848730', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848731', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848725', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848701', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848683', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848682', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848689', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848713', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848700', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848694', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848688', 'drugName': 'Abrocitinib', 'tradeNames_list': "['Cibinqo']", 'syns_list': "['Abrocitinib', 'Cibinqo', 'PF-04965842', 'Pf-04965842']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eczema', 'efo_term': 'Eczema', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.195 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of myocarditis? | In the context of myocarditis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocarditis%" OR LOWER(efo_term) LIKE "%myocarditis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218701', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219325', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219533', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219741', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220157', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220365', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220573', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220781', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219117', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218285', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217869', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217661', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219949', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218909', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218493', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218077', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocarditis', 'efo_term': 'myocarditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.444 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361090', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361249', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361302', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361355', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361461', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361514', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361567', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361673', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361726', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361779', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361832', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361938', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361991', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362044', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362097', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362150', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362203', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362256', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362309', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362362', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362415', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362521', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362574', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362627', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362680', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362733', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362839', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362892', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362945', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362998', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363051', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363104', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363157', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363210', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363263', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363316', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363369', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363422', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363475', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363528', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363581', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363634', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363687', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363740', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363793', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363846', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363899', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363952', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364005', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364058', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364111', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364217', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364270', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364323', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364376', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364429', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364482', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364588', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364641', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364694', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364747', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364800', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364853', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364906', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364959', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365012', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365065', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365118', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365171', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365224', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365277', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365330', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365383', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365436', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365489', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365542', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365595', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365648', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365701', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365754', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365807', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365860', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365913', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365966', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366019', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366072', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364164', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362468', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361620', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361196', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360984', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360878', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360825', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364535', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362786', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361885', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361408', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361143', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361037', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360931', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.577 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of sprain? | In the context of sprain, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sprain%" OR LOWER(efo_term) LIKE "%sprain%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638367', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638712', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638827', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638942', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639172', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639287', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639402', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639632', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639747', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639862', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639977', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640207', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640322', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640437', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640552', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640667', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640782', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640897', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641012', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641127', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641242', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641472', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641587', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641702', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641817', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641932', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642162', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642277', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642392', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642507', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642622', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642737', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642852', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642967', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643082', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643197', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643312', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643427', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643542', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643657', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643772', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643887', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644002', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644117', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644232', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644347', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644462', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644577', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641357', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639517', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638597', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638137', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637907', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637792', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642047', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640092', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639057', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638482', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638252', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638022', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.953 | Q34 | What are the names of the genes that are targeted by the drug Meloxicam in the treatment of rheumatic disease? | In the context of rheumatic disease, the drug Meloxicam targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatic disease%" OR LOWER(efo_term) LIKE "%rheumatic disease%") AND (LOWER(drugName) LIKE "%meloxicam%" OR LOWER(tradeNames_list) LIKE "%meloxicam%" OR LOWER(syns_list) LIKE "%meloxicam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842375', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842420', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842435', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842450', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842480', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842495', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842510', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842540', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842525', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842405', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842345', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842300', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842315', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842465', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842390', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842360', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842330', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.507 | Q34 | What are the names of the genes that are targeted by the drug Doxepin Hydrochloride in the treatment of unipolar depression? | In the context of unipolar depression, the drug Doxepin Hydrochloride targets the gene solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%doxepin hydrochloride%" OR LOWER(tradeNames_list) LIKE "%doxepin hydrochloride%" OR LOWER(syns_list) LIKE "%doxepin hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440792', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440807', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440808', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440815', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440823', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440824', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440831', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440839', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440840', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440847', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440848', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440856', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440863', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440864', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440871', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440872', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440879', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440880', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440887', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440888', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440895', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440903', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440904', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440911', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440912', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440919', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440927', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440928', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440935', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440936', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440943', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440944', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440951', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440952', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440959', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440960', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440967', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440968', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440975', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440976', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440983', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440984', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440991', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440992', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440999', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_441000', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_441007', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_441008', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440896', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440832', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440800', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440784', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440776', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440775', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440920', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440855', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440816', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440799', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440791', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440783', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depression', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.610 | Q34 | What are the names of the genes that are targeted by the drug Bupivacaine Hydrochloride in the treatment of pain? | In the context of pain, the drug Bupivacaine Hydrochloride targets the gene sodium voltage-gated channel alpha subunit 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%bupivacaine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%bupivacaine hydrochloride%" OR LOWER(syns_list) LIKE "%bupivacaine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_664030', 'drugName': 'Bupivacaine Hydrochloride', 'tradeNames_list': "['Bupivac hcl', 'Bupivacaine hydrochloride', 'Bupivacaine hydrochloride kitBupivacaine hydrochloride preservative free', 'Marcain', 'MarcaineMarcaine hydrochloride', 'Marcaine hydrochloride preservative freeSensorcaine', 'Xaracoll']", 'syns_list': "['AH-2250', 'Bupivacaine hcl', 'Bupivacaine hydrochlorideBupivacaine hydrochloride hydrateBupivacaine hydrochloride monohydrate', 'Bupivacaine hydrochloride rsBupivacaini hydrochloridum', 'Carbostesin', 'LAC-43', 'NSC-758631WIN 11,318', 'WIN-11318', 'Xaracoll']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_664018', 'drugName': 'Bupivacaine Hydrochloride', 'tradeNames_list': "['Bupivac hcl', 'Bupivacaine hydrochloride', 'Bupivacaine hydrochloride kitBupivacaine hydrochloride preservative free', 'Marcain', 'MarcaineMarcaine hydrochloride', 'Marcaine hydrochloride preservative freeSensorcaine', 'Xaracoll']", 'syns_list': "['AH-2250', 'Bupivacaine hcl', 'Bupivacaine hydrochlorideBupivacaine hydrochloride hydrateBupivacaine hydrochloride monohydrate', 'Bupivacaine hydrochloride rsBupivacaini hydrochloridum', 'Carbostesin', 'LAC-43', 'NSC-758631WIN 11,318', 'WIN-11318', 'Xaracoll']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1849 | Q34 | What are the names of the genes that are targeted by the drug Simvastatin in the treatment of familial hypercholesterolemia? | In the context of familial hypercholesterolemia, the drug Simvastatin targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial hypercholesterolemia%" OR LOWER(efo_term) LIKE "%familial hypercholesterolemia%") AND (LOWER(drugName) LIKE "%simvastatin%" OR LOWER(tradeNames_list) LIKE "%simvastatin%" OR LOWER(syns_list) LIKE "%simvastatin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103901', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103797', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104109', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104005', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1635 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of venous thromboembolism? | Dabigatran has not been approved by the FDA as a treatment for venous thromboembolism, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%venous thromboembolism%" OR LOWER(efo_term) LIKE "%venous thromboembolism%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092726', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092765', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092778', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092791', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092817', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092830', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092843', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092869', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092882', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092895', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092908', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092934', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092947', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092960', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092973', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092986', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092999', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093012', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093025', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093038', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093051', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093077', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093090', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093103', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093116', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093129', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093155', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093168', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093181', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093194', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093207', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093220', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093233', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093246', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093259', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093272', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093285', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093298', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093311', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093324', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093337', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093350', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093363', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093376', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093389', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093413', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093424', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093435', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093446', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093457', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093468', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093490', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093501', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093512', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093523', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093534', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093545', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093567', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093578', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093589', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093600', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093611', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093622', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093633', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093644', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093655', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093666', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093677', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093688', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093699', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093710', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093721', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093732', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093743', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093754', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093765', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093776', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093787', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093798', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093809', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093820', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093831', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093842', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093853', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093864', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093875', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093479', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093064', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092856', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092752', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092700', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092674', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092661', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093556', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093142', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092921', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092804', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092739', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092713', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092687', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Venous Thromboembolism', 'efo_term': 'venous thromboembolism', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1770 | Q34 | What are the names of the genes that are targeted by the drug Ibandronate Sodium in the treatment of osteoporosis? | In the context of osteoporosis, the drug Ibandronate Sodium targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoporosis%" OR LOWER(efo_term) LIKE "%osteoporosis%") AND (LOWER(drugName) LIKE "%ibandronate sodium%" OR LOWER(tradeNames_list) LIKE "%ibandronate sodium%" OR LOWER(syns_list) LIKE "%ibandronate sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099485', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099475', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099474', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099480', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099484', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099479', 'drugName': 'Ibandronate Sodium', 'tradeNames_list': "['Boniva', 'Ibandronate sodium']", 'syns_list': "['BM 21.0955 NA H20', 'BM-21.0955', 'BM-210955Ibandronate monosodium monohydrate', 'Ibandronate sodiumIbandronate sodium hydrate', 'Ibandronate sodium monohydrateIbandronic acid sodium salt', 'Ibandronic acid sodium salt monohydrateIbandronic sodium monohydrate', 'NSC-759815']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.852 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833505', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833394', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833283', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832950', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833061', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833172', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833470', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833477', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833033', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833248', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833255', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833144', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832915', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832922', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833026', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833137', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833359', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833366', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.4 | Q34 | What are the names of the genes that are targeted by the drug Loxapine in the treatment of psychosis? | In the context of psychosis, the drug Loxapine targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2, dopamine receptor D3, dopamine receptor D4 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psychosis%" OR LOWER(efo_term) LIKE "%psychosis%") AND (LOWER(drugName) LIKE "%loxapine%" OR LOWER(tradeNames_list) LIKE "%loxapine%" OR LOWER(syns_list) LIKE "%loxapine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149112', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149148', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149160', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149172', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149196', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149208', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149220', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149244', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149256', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149268', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149280', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149304', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149316', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149328', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149340', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149352', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149364', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149376', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149388', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149400', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149412', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149436', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149448', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149460', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149424', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149232', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149088', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149064', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149052', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149136', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149292', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149184', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149124', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149100', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149076', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1469 | Q34 | What are the names of the genes that are targeted by the drug Diroximel Fumarate in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Diroximel Fumarate targets the gene kelch like ECH associated protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%diroximel fumarate%" OR LOWER(tradeNames_list) LIKE "%diroximel fumarate%" OR LOWER(syns_list) LIKE "%diroximel fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055623', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055626', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055629', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055621', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055627', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055624', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1445 | Q34 | What are the names of the genes that are targeted by the drug Liraglutide in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Liraglutide targets the gene glucagon like peptide 1 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%liraglutide%" OR LOWER(tradeNames_list) LIKE "%liraglutide%" OR LOWER(syns_list) LIKE "%liraglutide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1044954', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044425', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044862', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044470', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044446', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044724', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044493', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044448', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044816', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044516', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045045', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044908', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044539', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045114', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044471', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044701', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044562', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045137', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044492', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044747', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044585', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044494', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044793', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044608', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045021', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044515', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044631', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045067', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044517', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044885', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044654', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045068', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044538', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044931', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044677', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045136', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044540', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044699', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044700', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045115', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044561', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044722', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044723', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045159', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044563', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044745', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044746', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045138', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044584', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044768', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044769', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044586', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044791', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044792', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044999', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044607', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044814', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045023', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044609', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044837', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044838', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045022', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044630', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044860', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044861', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045091', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044632', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044883', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044884', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045046', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044653', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044906', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044907', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045090', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044655', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044929', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044930', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045069', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044676', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044952', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044953', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045160', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044678', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044975', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044976', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045182', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045161', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045092', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045044', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045000', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044998', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044977', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044770', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044815', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044839', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044469', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045113', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044447', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044423', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044424', 'drugName': 'Liraglutide', 'tradeNames_list': "['Saxenda', 'Victoza']", 'syns_list': "['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'MODY', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.471 | Q34 | What are the names of the genes that are targeted by the drug Oxymetazoline Hydrochloride in the treatment of rosacea? | In the context of rosacea, the drug Oxymetazoline Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rosacea%" OR LOWER(efo_term) LIKE "%rosacea%") AND (LOWER(drugName) LIKE "%oxymetazoline hydrochloride%" OR LOWER(tradeNames_list) LIKE "%oxymetazoline hydrochloride%" OR LOWER(syns_list) LIKE "%oxymetazoline hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_417244', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417274', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417284', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417294', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417314', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417324', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417334', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417354', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417364', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417374', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417384', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417404', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417414', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417424', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417434', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417444', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417454', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417464', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417474', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417484', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417494', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417514', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417524', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417534', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417544', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417554', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417574', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417584', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417594', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417604', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417614', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417624', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417634', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417644', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417654', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417664', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417674', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417684', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417694', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417704', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417714', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417724', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417734', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417744', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417754', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417764', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417774', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417784', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417794', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417804', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417814', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417834', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417844', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417854', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417864', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417874', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417884', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417904', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417914', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417924', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417934', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417944', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417954', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417964', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417974', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417984', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417994', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418004', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418014', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418024', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418034', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418044', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418054', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418064', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418074', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418084', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418094', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418104', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418114', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418124', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418134', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418144', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418154', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418164', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418174', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418184', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_417824', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417504', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417344', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417264', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417224', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417204', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417194', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417894', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417564', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417394', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417304', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417254', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417234', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417214', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.323 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of keratitis? | In the context of keratitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%keratitis%" OR LOWER(efo_term) LIKE "%keratitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227779', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228634', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228919', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229204', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229774', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230059', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230344', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230914', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231199', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231484', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231769', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232339', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230629', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228349', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227209', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226639', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226354', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232054', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229489', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228064', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227494', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226924', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratitis', 'efo_term': 'keratitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.6 | Q34 | What are the names of the genes that are targeted by the drug Loxapine in the treatment of schizophrenia? | In the context of schizophrenia, the drug Loxapine targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2, dopamine receptor D3, dopamine receptor D4 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%loxapine%" OR LOWER(tradeNames_list) LIKE "%loxapine%" OR LOWER(syns_list) LIKE "%loxapine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149114', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149150', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149162', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149174', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149198', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149210', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149222', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149246', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149258', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149270', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149282', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149306', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149318', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149330', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149342', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149354', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149366', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149378', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_149390', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149402', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149414', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149438', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149450', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149462', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149426', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_149234', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149090', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149066', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149054', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149138', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149294', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_149186', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149126', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149102', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149078', 'drugName': 'Loxapine', 'tradeNames_list': "['Adasuve', 'Loxitane intramuscular [as hydrochloride]Loxitane-c oral suspension [as hydrochloride]']", 'syns_list': "['CL 62,362', 'CL-62362', 'Loxapac', 'Loxapine', 'Loxitane', 'SUM 3170SUM-3170']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.224 | Q34 | What are the names of the genes that are targeted by the drug Betamethasone Dipropionate in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Betamethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%betamethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%betamethasone dipropionate%" OR LOWER(syns_list) LIKE "%betamethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220891', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220867', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220843', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220831', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220903', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220879', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220855', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1404 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of bacterial disease? | In the context of bacterial disease, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bacterial disease%" OR LOWER(efo_term) LIKE "%bacterial disease%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038218', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038443', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038518', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038593', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038743', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038818', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038893', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039043', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039118', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039193', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039268', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039418', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039493', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039568', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039643', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039718', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039793', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039868', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039943', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040018', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040093', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040243', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040318', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040393', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040468', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040543', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040693', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040768', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040843', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040918', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040993', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041068', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040168', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038968', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038368', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038068', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037918', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037843', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040618', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039343', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038668', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038293', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038143', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037993', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.551 | Q34 | What are the names of the genes that are targeted by the drug Levocetirizine Dihydrochloride in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Levocetirizine Dihydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%levocetirizine dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%levocetirizine dihydrochloride%" OR LOWER(syns_list) LIKE "%levocetirizine dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455995', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_list': "['Levocetirizine dihydrochloride', 'Xusal', 'Xyzal', 'Xyzal allergy 24hrXyzall']", 'syns_list': "['Cetirizine (r)-form dihydrochloride', 'Cetirizine hydrochloride (r)-Levocetirizine dihydrochloride', 'Levocetirizine hydrochlorideLevocetirizine monohydrochloride', 'NSC-758898', 'UCB 28556', 'UCB-28556']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.230 | Q34 | What are the names of the genes that are targeted by the drug Betamethasone Dipropionate in the treatment of psoriasis vulgaris? | In the context of psoriasis vulgaris, the drug Betamethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis vulgaris%" OR LOWER(efo_term) LIKE "%psoriasis vulgaris%") AND (LOWER(drugName) LIKE "%betamethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%betamethasone dipropionate%" OR LOWER(syns_list) LIKE "%betamethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220897', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220873', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220849', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220837', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220909', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220885', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220861', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.40 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of autism? | In the context of autism, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%autism%" OR LOWER(efo_term) LIKE "%autism%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158027', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158045', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158051', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158057', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158069', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158075', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158081', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158093', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158099', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158105', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158111', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158123', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158129', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158135', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158141', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158147', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158153', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158159', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158165', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158171', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158177', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158189', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158195', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158201', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158207', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158213', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158225', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158231', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158237', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158243', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158249', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158255', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158261', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158267', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158273', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158279', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158285', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158291', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158297', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158303', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158309', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158315', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158321', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158327', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158333', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158339', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158345', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158351', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158357', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158363', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158369', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158381', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158387', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158393', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158399', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158405', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158411', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158423', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158429', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158435', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158441', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158447', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158453', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158459', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158465', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158471', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158477', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158483', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158489', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158495', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158501', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158507', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158513', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158519', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158525', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158531', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158537', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158543', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158549', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158555', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158561', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158567', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158573', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158579', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158585', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158591', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158375', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158183', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158087', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158039', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158015', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158003', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_157997', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158417', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158219', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158117', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158063', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158033', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158021', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158009', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autistic Disorder', 'efo_term': 'autism', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.546 | Q34 | What are the names of the genes that are targeted by the drug Olopatadine Hydrochloride in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Olopatadine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%olopatadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%olopatadine hydrochloride%" OR LOWER(syns_list) LIKE "%olopatadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455962', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455969', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455970', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455973', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455966', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455958', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455954', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455953', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455974', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455965', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455961', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455957', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.244 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222009', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222137', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222139', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222202', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222267', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222269', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222332', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222334', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222074', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221944', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221879', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221877', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222204', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222072', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222007', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221942', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.904 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of Arthralgia? | In the context of Arthralgia, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arthralgia%" OR LOWER(efo_term) LIKE "%arthralgia%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838532', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838655', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838696', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838737', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838819', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838860', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838901', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838983', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839024', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839065', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839106', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839188', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839229', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839270', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839311', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839352', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839393', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839434', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839475', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839516', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839557', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839639', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839680', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839598', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838942', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838614', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838368', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838327', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838450', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839147', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838778', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838573', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838491', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838409', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthralgia', 'efo_term': 'Arthralgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1121 | Q34 | What are the names of the genes that are targeted by the drug Levothyroxine Sodium in the treatment of congenital hypothyroidism? | In the context of congenital hypothyroidism, the drug Levothyroxine Sodium targets the gene thyroid hormone receptor alpha and thyroid hormone receptor beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congenital hypothyroidism%" OR LOWER(efo_term) LIKE "%congenital hypothyroidism%") AND (LOWER(drugName) LIKE "%levothyroxine sodium%" OR LOWER(tradeNames_list) LIKE "%levothyroxine sodium%" OR LOWER(syns_list) LIKE "%levothyroxine sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924837', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924858', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924865', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924872', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924886', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924893', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924900', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924914', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924921', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924928', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924935', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924949', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924956', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924963', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924970', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924977', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924984', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924991', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924998', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925005', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925012', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925026', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925033', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925040', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925047', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925054', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925068', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925075', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925082', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925089', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925096', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925103', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925110', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925117', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925124', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925131', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925138', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925145', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925152', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925159', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925166', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925173', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925180', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925187', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925194', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925201', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925208', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925215', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925222', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925229', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925236', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925250', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925257', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925264', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925271', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925278', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925285', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925299', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925306', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925313', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925320', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925327', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925334', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925341', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925348', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925355', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925362', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925369', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925376', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925383', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925390', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925397', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925404', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925411', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925418', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925425', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925432', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925439', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925446', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925453', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925460', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925467', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925474', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925481', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925488', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925495', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925243', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925019', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924907', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924851', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924823', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924809', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924802', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925292', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925061', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924942', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924879', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924844', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924830', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924816', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.138 | Q34 | What are the names of the genes that are targeted by the drug Dacomitinib in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Dacomitinib targets the gene epidermal growth factor receptor, erb-b2 receptor tyrosine kinase 2 and erb-b2 receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%dacomitinib%" OR LOWER(tradeNames_list) LIKE "%dacomitinib%" OR LOWER(syns_list) LIKE "%dacomitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217107', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217110', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217111', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217112', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217114', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217115', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217116', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217118', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217119', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217120', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217121', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217123', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217124', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217125', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217126', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217127', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217128', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217129', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217130', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217131', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217132', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217134', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217135', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217136', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217137', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217133', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_217109', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217105', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217103', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217102', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217117', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217122', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_217113', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217108', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217106', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217104', 'drugName': 'Dacomitinib', 'tradeNames_list': "['Vizimpro']", 'syns_list': "['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1179 | Q34 | What are the names of the genes that are targeted by the drug Sitagliptin Phosphate in the treatment of hyperlipidemia? | In the context of hyperlipidemia, the drug Sitagliptin Phosphate targets the gene dipeptidyl peptidase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyperlipidemia%" OR LOWER(efo_term) LIKE "%hyperlipidemia%") AND (LOWER(drugName) LIKE "%sitagliptin phosphate%" OR LOWER(tradeNames_list) LIKE "%sitagliptin phosphate%" OR LOWER(syns_list) LIKE "%sitagliptin phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933073', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933091', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933097', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933103', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933115', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933121', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933127', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933139', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933145', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933151', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933157', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933169', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933175', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933181', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933187', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933193', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933199', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933205', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933211', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933217', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933223', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933235', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933241', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933247', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933253', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933259', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933271', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933277', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933283', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933289', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933295', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933301', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933307', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933229', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933133', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933085', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933061', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933049', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933043', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933265', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933163', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933109', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933079', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933067', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933055', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipidemias', 'efo_term': 'hyperlipidemia', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1976 | Q34 | What are the names of the genes that are targeted by the drug Topotecan in the treatment of cancer? | In the context of cancer, the drug Topotecan targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%topotecan%" OR LOWER(tradeNames_list) LIKE "%topotecan%" OR LOWER(syns_list) LIKE "%topotecan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193672', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193577', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193578', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193650', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193649', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193661', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193568', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193641', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193569', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193567', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193643', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193660', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193628', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193571', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193556', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193671', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193639', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193640', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193551', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193549', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193667', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193545', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mediastinal Neoplasms', 'efo_term': 'mediastinal cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193617', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Mediastinal Neoplasms', 'efo_term': 'mediastinal cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193621', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193622', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193623', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193550', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193656', 'drugName': 'Topotecan', 'tradeNames_list': "['Hycamtin', 'Potactasol']", 'syns_list': "['Ff-10850 (liposomal topotecan)', 'Hycamptamine', 'Hycamptin', 'HycamtinNSC-609699', 'NSC-641007', 'Nogitecan', 'SKF-104864', 'Topotecan']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193602', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193530', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193508', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193525', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193597', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193580', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1558 | Q34 | What are the names of the genes that are targeted by the drug Ambrisentan in the treatment of hypertension? | In the context of hypertension, the drug Ambrisentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%ambrisentan%" OR LOWER(tradeNames_list) LIKE "%ambrisentan%" OR LOWER(syns_list) LIKE "%ambrisentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084059', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084062', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084063', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084071', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084073', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084074', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084075', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084084', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084085', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084086', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084087', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084096', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084097', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084098', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084099', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084107', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084108', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084109', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084110', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084111', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084119', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084121', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084122', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084123', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084131', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084132', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084134', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084135', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084143', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084144', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084145', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084146', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084147', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084155', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084156', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084157', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084158', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084159', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084167', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084168', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084169', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084170', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084171', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084179', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084180', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084181', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084182', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084183', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084120', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084083', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084061', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084050', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084048', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084047', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084133', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084095', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084072', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084060', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084051', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084049', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.997 | Q34 | What are the names of the genes that are targeted by the drug Umeclidinium Bromide in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Umeclidinium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%umeclidinium bromide%" OR LOWER(tradeNames_list) LIKE "%umeclidinium bromide%" OR LOWER(syns_list) LIKE "%umeclidinium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857414', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857429', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857434', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857424', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857394', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857389', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857404', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857419', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857409', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857399', 'drugName': 'Umeclidinium Bromide', 'tradeNames_list': "['Incruse ellipta']", 'syns_list': "['Anoro ellipta', 'GSK-573719A', 'GSK573719A', 'Umeclidinium bromUmeclidinium bromide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.835 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of pharyngitis? | In the context of pharyngitis, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pharyngitis%" OR LOWER(efo_term) LIKE "%pharyngitis%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_829267', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829582', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829687', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829792', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830002', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830107', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830212', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830422', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830527', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830632', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830737', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830947', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831052', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831157', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831262', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831367', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831472', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831577', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831682', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831787', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831892', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832102', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832207', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832312', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832417', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832522', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832732', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832837', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831997', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830317', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829477', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829057', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828847', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828742', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832627', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830842', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829897', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829372', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829162', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828952', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.449 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of sinusitis? | In the context of sinusitis, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sinusitis%" OR LOWER(efo_term) LIKE "%sinusitis%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361096', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361255', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361308', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361361', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361467', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361520', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361573', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361679', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361732', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361785', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361838', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361944', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361997', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362050', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362103', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362156', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362209', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362262', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362315', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362368', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362421', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362527', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362580', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362633', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362686', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362739', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362845', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362898', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362951', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363004', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363057', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363110', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363163', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363216', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363269', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363322', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363375', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363428', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363481', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363534', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363587', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363640', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363693', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363746', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363799', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363852', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363905', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363958', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364011', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364064', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364117', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364223', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364276', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364329', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364382', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364435', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364488', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364594', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364647', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364700', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364753', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364806', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364859', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364912', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364965', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365018', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365071', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365124', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365177', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365230', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365283', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365336', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365389', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365442', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365495', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365548', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365601', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365654', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365707', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365760', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365813', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365866', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365919', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365972', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366025', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366078', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364170', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362474', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361626', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361202', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360990', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360884', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360831', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364541', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362792', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361891', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361414', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361149', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361043', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360937', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.848 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of rheumatic disease? | In the context of rheumatic disease, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatic disease%" OR LOWER(efo_term) LIKE "%rheumatic disease%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833501', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833057', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832946', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833279', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833390', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833168', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1075 | Q34 | What are the names of the genes that are targeted by the drug Testosterone Cypionate in the treatment of neoplasm? | In the context of neoplasm, the drug Testosterone Cypionate targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%testosterone cypionate%" OR LOWER(tradeNames_list) LIKE "%testosterone cypionate%" OR LOWER(syns_list) LIKE "%testosterone cypionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921013', 'drugName': 'Testosterone Cypionate', 'tradeNames_list': "['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'TestosteroneTestosterone cypionate']", 'syns_list': "['Depo-Testadiol', 'NSC-9157Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionateTestosterone cyclopentylpropionate', 'Testosterone cypionateTestosterone cypionate ciii']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921010', 'drugName': 'Testosterone Cypionate', 'tradeNames_list': "['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'TestosteroneTestosterone cypionate']", 'syns_list': "['Depo-Testadiol', 'NSC-9157Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionateTestosterone cyclopentylpropionate', 'Testosterone cypionateTestosterone cypionate ciii']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921009', 'drugName': 'Testosterone Cypionate', 'tradeNames_list': "['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'TestosteroneTestosterone cypionate']", 'syns_list': "['Depo-Testadiol', 'NSC-9157Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionateTestosterone cyclopentylpropionate', 'Testosterone cypionateTestosterone cypionate ciii']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921012', 'drugName': 'Testosterone Cypionate', 'tradeNames_list': "['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'TestosteroneTestosterone cypionate']", 'syns_list': "['Depo-Testadiol', 'NSC-9157Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionateTestosterone cyclopentylpropionate', 'Testosterone cypionateTestosterone cypionate ciii']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1403 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of periodontitis? | In the context of periodontitis, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%periodontitis%" OR LOWER(efo_term) LIKE "%periodontitis%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038217', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040842', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040017', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038142', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039267', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039117', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1040767', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039417', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1040092', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040167', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040242', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040692', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1038067', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040617', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039492', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037842', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039867', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038742', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038442', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038292', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040317', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1038892', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039792', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039342', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039942', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040392', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040542', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1038592', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038517', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038667', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037992', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038817', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037917', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039642', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038967', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039042', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039717', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040992', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1038367', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040917', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041067', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039192', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1040467', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039567', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037107', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037404', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037415', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037492', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037481', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037470', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037459', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037448', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037437', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037426', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037503', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037679', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1036887', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037393', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1036920', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037030', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037250', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036964', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037118', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037129', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037701', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037261', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037712', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037041', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037272', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037734', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037283', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037756', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037767', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1036931', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037052', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037294', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036975', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037778', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037305', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037063', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037745', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037316', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037327', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037723', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1036843', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036876', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036942', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037074', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037690', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037338', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037349', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037085', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037360', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1036865', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037371', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1036953', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037096', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037382', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037140', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037151', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Periodontitis', 'efo_term': 'periodontitis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1142 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of meningioma? | Trametinib has not been approved by the FDA as a treatment for meningioma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%meningioma%" OR LOWER(efo_term) LIKE "%meningioma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928690', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928810', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928850', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928890', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928970', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929010', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929050', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929130', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929170', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929210', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929250', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929330', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929370', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929410', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929450', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929490', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929530', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929570', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929610', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929650', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929690', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929770', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929810', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929850', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929890', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929930', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930010', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930050', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930090', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930130', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930170', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930210', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930250', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930290', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930330', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930370', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930410', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930450', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930490', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930530', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930570', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930610', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930650', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930690', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930730', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930770', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930810', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930850', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930890', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930930', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930970', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931050', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931090', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931130', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931170', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931210', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931250', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931330', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931370', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931410', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931450', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931490', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931530', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931570', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931610', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931650', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931690', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931730', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931770', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931810', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931850', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931890', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931930', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931970', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932010', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932050', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932090', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932130', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932170', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932210', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932250', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932290', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932330', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932370', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932410', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932450', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931010', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929730', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929090', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928770', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928610', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928530', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928490', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931290', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929970', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929290', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928930', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928730', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928650', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928570', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1808 | Q34 | What are the names of the genes that are targeted by the drug Givosiran Sodium in the treatment of liver disease? | In the context of liver disease, the drug Givosiran Sodium targets the gene 5'-aminolevulinate synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%liver disease%" OR LOWER(efo_term) LIKE "%liver disease%") AND (LOWER(drugName) LIKE "%givosiran sodium%" OR LOWER(tradeNames_list) LIKE "%givosiran sodium%" OR LOWER(syns_list) LIKE "%givosiran sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100369', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100375', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100377', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100379', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100383', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100373', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100365', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100361', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100359', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100381', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100371', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100367', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100363', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.586 | Q34 | What are the names of the genes that are targeted by the drug Carbamazepine in the treatment of bipolar disorder? | In the context of bipolar disorder, the drug Carbamazepine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar disorder%" OR LOWER(efo_term) LIKE "%bipolar disorder%") AND (LOWER(drugName) LIKE "%carbamazepine%" OR LOWER(tradeNames_list) LIKE "%carbamazepine%" OR LOWER(syns_list) LIKE "%carbamazepine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_650938', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650967', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650970', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650983', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650999', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651002', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651015', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651031', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651034', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651047', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651050', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651066', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651079', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651082', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651095', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651098', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651111', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651114', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651127', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651130', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651143', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651159', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651162', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651175', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651178', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651191', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651207', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651210', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651223', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651226', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651239', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651242', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651255', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651258', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651271', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651274', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651287', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651290', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651303', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651306', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651319', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651322', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651335', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651338', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651351', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651354', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651367', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651370', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651383', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651386', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651399', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651415', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651418', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651431', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651434', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651447', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651450', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651466', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651479', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651482', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651495', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651498', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651511', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651514', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651527', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651530', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651543', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651546', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651559', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651562', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651575', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651578', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651591', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651594', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651607', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651610', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651623', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651626', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651639', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651642', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651655', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651658', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651671', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651674', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651687', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651690', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651402', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651146', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651018', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650954', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650922', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650906', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650903', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651463', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651194', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651063', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650986', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650951', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650935', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650919', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1748 | Q34 | What are the names of the genes that are targeted by the drug Esomeprazole Magnesium in the treatment of Zollinger-Ellison Syndrome? | In the context of Zollinger-Ellison Syndrome, the drug Esomeprazole Magnesium targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%zollinger-ellison syndrome%" OR LOWER(efo_term) LIKE "%zollinger-ellison syndrome%") AND (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_list) LIKE "%esomeprazole magnesium%" OR LOWER(syns_list) LIKE "%esomeprazole magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097875', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097863', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097899', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097887', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Zollinger-Ellison Syndrome', 'efo_term': 'Zollinger-Ellison Syndrome', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1950 | Q34 | What are the names of the genes that are targeted by the drug Sodium Oxybate in the treatment of narcolepsy? | In the context of narcolepsy, the drug Sodium Oxybate targets the gene gamma-aminobutyric acid type B receptor subunit 1 and gamma-aminobutyric acid type B receptor subunit 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%narcolepsy%" OR LOWER(efo_term) LIKE "%narcolepsy%") AND (LOWER(drugName) LIKE "%sodium oxybate%" OR LOWER(tradeNames_list) LIKE "%sodium oxybate%" OR LOWER(syns_list) LIKE "%sodium oxybate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192730', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192753', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192754', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192765', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192777', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192778', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192789', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192801', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192802', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192813', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192814', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192826', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192837', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192838', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192849', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192850', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192861', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192862', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192873', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192874', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192885', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192897', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192898', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192909', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192910', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192921', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192933', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192934', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192945', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192946', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192957', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192958', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192969', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192970', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192981', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192982', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192993', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192994', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193005', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193006', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193017', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193018', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193029', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193030', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193041', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193042', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193053', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193054', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193065', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193066', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193077', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193089', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193090', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193101', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193102', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193078', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192886', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192742', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192718', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192706', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192705', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192790', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192922', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192825', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192766', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192741', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192729', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192717', 'drugName': 'Sodium Oxybate', 'tradeNames_list': "['Xyrem']", 'syns_list': "['.gamma.-hydroxybutyrate sodium salt', 'Catabate', 'Lumryz', 'NSC-84223Oxybate sodium', 'Sodium oxybat', 'Sodium oxybate', 'Sodium oxybutyrateWY-3478']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.666 | Q34 | What are the names of the genes that are targeted by the drug Roflumilast in the treatment of chronic obstructive pulmonary disease? | In the context of chronic obstructive pulmonary disease, the drug Roflumilast targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic obstructive pulmonary disease%" OR LOWER(efo_term) LIKE "%chronic obstructive pulmonary disease%") AND (LOWER(drugName) LIKE "%roflumilast%" OR LOWER(tradeNames_list) LIKE "%roflumilast%" OR LOWER(syns_list) LIKE "%roflumilast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695490', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695553', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695574', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695595', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695637', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695658', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695679', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695721', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695742', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695763', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695784', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695826', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695847', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695868', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695889', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695910', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695931', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695952', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695973', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695994', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696015', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696057', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696078', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696099', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696120', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696141', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696183', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696204', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696225', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696246', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696267', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696288', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696309', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696330', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696351', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696372', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696393', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696414', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696435', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696456', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696477', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696498', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696519', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696540', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696036', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695700', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695532', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695448', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695406', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695385', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696162', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695805', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695616', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695511', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695469', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695427', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.440 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of Mydriasis? | In the context of Mydriasis, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mydriasis%" OR LOWER(efo_term) LIKE "%mydriasis%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361086', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361245', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361298', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361351', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361457', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361510', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361563', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361669', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361722', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361775', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361828', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361934', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361987', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362040', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362093', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362146', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362199', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362252', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362305', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362358', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362411', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362517', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362570', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362623', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362676', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362729', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362835', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362888', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362941', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362994', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363047', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363100', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363153', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363206', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363259', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363312', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363365', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363418', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363471', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363524', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363577', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363630', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363683', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363736', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363789', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363842', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363895', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363948', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364001', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364054', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364107', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364213', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364266', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364319', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364372', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364425', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364478', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364584', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364637', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364690', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364743', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364796', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364849', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364902', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364955', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365008', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365061', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365114', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365167', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365220', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365273', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365326', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365379', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365432', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365485', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365538', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365591', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365644', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365697', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365750', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365803', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365856', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365909', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365962', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366015', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366068', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364160', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362464', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361616', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361192', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360980', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360874', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360821', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364531', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362782', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361881', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361404', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361139', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361033', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360927', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mydriasis', 'efo_term': 'Mydriasis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1839 | Q34 | What are the names of the genes that are targeted by the drug Crofelemer in the treatment of Diarrhea? | In the context of Diarrhea, the drug Crofelemer targets the gene CF transmembrane conductance regulator and anoctamin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diarrhea%" OR LOWER(efo_term) LIKE "%diarrhea%") AND (LOWER(drugName) LIKE "%crofelemer%" OR LOWER(tradeNames_list) LIKE "%crofelemer%" OR LOWER(syns_list) LIKE "%crofelemer%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103274', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1103258', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103254', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103266', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1103270', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'ANO1', 'approvedName': 'anoctamin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1103262', 'drugName': 'Crofelemer', 'tradeNames_list': "['Fulyzaq', 'Mytesi', 'Provir', 'Virend']", 'syns_list': "['Crofelemer', 'NP-303', 'SP-303', 'TRN-002']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diarrhea', 'efo_term': 'Diarrhea', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.378 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of otitis externa? | In the context of otitis externa, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%otitis externa%" OR LOWER(efo_term) LIKE "%otitis externa%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_241227', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241473', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241555', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241637', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241801', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241883', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241391', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241063', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240899', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240817', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241719', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241309', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241145', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240981', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Otitis Externa', 'efo_term': 'otitis externa', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1463 | Q34 | What are the names of the genes that are targeted by the drug Tazarotene in the treatment of psoriasis vulgaris? | In the context of psoriasis vulgaris, the drug Tazarotene targets the gene retinoic acid receptor gamma, retinoic acid receptor beta and retinoic acid receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis vulgaris%" OR LOWER(efo_term) LIKE "%psoriasis vulgaris%") AND (LOWER(drugName) LIKE "%tazarotene%" OR LOWER(tradeNames_list) LIKE "%tazarotene%" OR LOWER(syns_list) LIKE "%tazarotene%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055501', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055525', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055533', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055541', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055517', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055485', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055469', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055461', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055549', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055509', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055493', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055477', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.972 | Q34 | What are the names of the genes that are targeted by the drug Tofacitinib Citrate in the treatment of psoriatic arthritis? | In the context of psoriatic arthritis, the drug Tofacitinib Citrate targets the gene Janus kinase 1, Janus kinase 3, tyrosine kinase 2 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriatic arthritis%" OR LOWER(efo_term) LIKE "%psoriatic arthritis%") AND (LOWER(drugName) LIKE "%tofacitinib citrate%" OR LOWER(tradeNames_list) LIKE "%tofacitinib citrate%" OR LOWER(syns_list) LIKE "%tofacitinib citrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_848325', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848340', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848345', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848350', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848360', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848365', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848370', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848380', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848385', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848390', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848395', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848405', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848410', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848415', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848420', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848425', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848430', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848435', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848440', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848445', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848450', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848460', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848465', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848470', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848475', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848480', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848490', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848495', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848500', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848505', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848510', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848515', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848520', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848525', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848530', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848535', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848540', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848545', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848550', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848555', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848560', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848565', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848570', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848575', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848580', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848585', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848590', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848595', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848600', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848605', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848610', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848620', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848625', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848630', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848635', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848640', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848645', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848655', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848660', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848665', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848670', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848675', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848615', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848455', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848375', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848335', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848315', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848305', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848300', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848650', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_848485', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848400', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_848355', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848330', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848320', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_848310', 'drugName': 'Tofacitinib Citrate', 'tradeNames_list': "['Xeljanz', 'Xeljanz xr']", 'syns_list': "['CP-690,550-10', 'CP-690550-10', 'Cp-690550 citrate', 'Tasocitinib citrateTasocitinib monocitrate', 'Tofacitinib citrate', 'Tofacitinib monocitrate']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1198 | Q34 | What are the names of the genes that are targeted by the drug Crizotinib in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Crizotinib targets the gene MET proto-oncogene, receptor tyrosine kinase, ALK receptor tyrosine kinase, EMAP like 4 and nucleophosmin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%crizotinib%" OR LOWER(tradeNames_list) LIKE "%crizotinib%" OR LOWER(syns_list) LIKE "%crizotinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_934400', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934466', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934488', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934510', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934554', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934576', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934598', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934642', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934664', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934686', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934708', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934752', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934774', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934796', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934818', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934840', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934862', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934884', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934906', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934928', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934950', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934994', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935016', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935038', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935060', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935082', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935126', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935148', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935170', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935192', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935214', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935236', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935258', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935280', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935302', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935324', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935346', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935368', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935390', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935412', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935434', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935456', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935478', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935500', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935522', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935544', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935566', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935588', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935610', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935632', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935654', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935698', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935720', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935742', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935764', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935786', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935808', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_935852', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935874', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935896', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935918', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935940', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935962', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935984', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936006', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936028', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936050', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936072', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936094', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_936116', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935676', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_934972', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934620', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934444', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934356', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934312', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934290', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_935830', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'NPM1', 'approvedName': 'nucleophosmin 1'}, {'UUID': 'DrugTargetsIndication121923_text_935104', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934730', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934532', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934422', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934378', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934334', 'drugName': 'Crizotinib', 'tradeNames_list': "['Xalkori']", 'syns_list': "['Crizotinib', 'NSC-756645', 'PF-02341066', 'PF-2341066', 'Pf-2341066']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.316 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227772', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228627', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228912', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229197', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229767', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230052', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230907', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231192', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231477', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231762', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230622', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227202', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226632', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226347', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232047', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229482', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228057', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227487', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226917', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1721 | Q34 | What are the names of the genes that are targeted by the drug Brivaracetam in the treatment of Seizure? | In the context of Seizure, the drug Brivaracetam targets the gene synaptic vesicle glycoprotein 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seizure%" OR LOWER(efo_term) LIKE "%seizure%") AND (LOWER(drugName) LIKE "%brivaracetam%" OR LOWER(tradeNames_list) LIKE "%brivaracetam%" OR LOWER(syns_list) LIKE "%brivaracetam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097449', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097467', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097473', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097479', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097491', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097461', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097437', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097425', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097419', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097485', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097455', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097443', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097431', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.446 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of angioedema? | In the context of angioedema, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%angioedema%" OR LOWER(efo_term) LIKE "%angioedema%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361093', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361252', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361305', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361358', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361464', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361517', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361570', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361676', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361729', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361782', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361835', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361941', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361994', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362047', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362100', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362153', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362206', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362259', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362312', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362365', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362418', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362524', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362577', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362630', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362683', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362736', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362842', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362895', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362948', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363001', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363054', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363107', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363160', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363213', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363266', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363319', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363372', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363425', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363478', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363531', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363584', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363637', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363690', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363743', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363796', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363849', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363902', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363955', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364008', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364061', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364114', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364220', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364273', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364326', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364379', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364432', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364485', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364591', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364644', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364697', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364750', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364803', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364856', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364909', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364962', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365015', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365068', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365121', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365174', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365227', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365280', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365333', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365386', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365439', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365492', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365545', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365598', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365651', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365704', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365757', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365810', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365863', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365916', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365969', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366022', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366075', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364167', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362471', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361623', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361199', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360987', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360881', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360828', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364538', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362789', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361888', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361411', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361146', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361040', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360934', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1133 | Q34 | What are the names of the genes that are targeted by the drug Trametinib Dimethyl Sulfoxide in the treatment of lung cancer? | In the context of lung cancer, the drug Trametinib Dimethyl Sulfoxide targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lung cancer%" OR LOWER(efo_term) LIKE "%lung cancer%") AND (LOWER(drugName) LIKE "%trametinib dimethyl sulfoxide%" OR LOWER(tradeNames_list) LIKE "%trametinib dimethyl sulfoxide%" OR LOWER(syns_list) LIKE "%trametinib dimethyl sulfoxide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927767', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927788', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927795', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927802', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927816', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927823', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927830', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927844', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927851', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927858', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927865', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927879', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927886', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927893', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927900', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927907', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927914', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927921', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927928', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927935', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927942', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927956', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927963', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927970', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927977', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927984', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927998', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928005', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928012', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928019', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928026', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928033', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928040', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928047', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928054', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928061', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928068', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928075', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928082', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928089', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928096', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928103', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928110', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928117', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928124', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928131', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928138', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928145', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928152', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928159', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928166', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928180', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928187', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928194', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928201', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928208', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928215', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928229', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928236', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928243', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928250', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928257', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928264', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928271', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928278', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928285', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928292', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928299', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928306', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928313', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928320', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928327', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928334', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928341', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928348', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928355', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928362', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928369', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928376', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928383', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928390', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928397', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928404', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928411', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928418', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928425', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928173', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927949', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927837', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927781', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927753', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927739', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927732', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928222', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927991', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927872', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927809', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927774', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927760', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927746', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.321 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of trichinosis? | In the context of trichinosis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%trichinosis%" OR LOWER(efo_term) LIKE "%trichinosis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227777', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228632', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228917', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229202', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229772', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230057', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230912', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231197', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231482', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231767', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230627', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228347', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227207', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226637', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226352', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232052', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229487', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228062', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227492', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226922', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Trichinellosis', 'efo_term': 'trichinosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.283 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227738', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228593', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228878', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229163', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229733', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230018', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230303', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230873', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231158', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231443', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231728', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232298', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230588', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228308', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227168', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226598', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226313', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232013', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229448', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228023', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227453', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226883', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.696 | Q34 | What are the names of the genes that are targeted by the drug Apixaban in the treatment of atrial fibrillation? | In the context of atrial fibrillation, the drug Apixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atrial fibrillation%" OR LOWER(efo_term) LIKE "%atrial fibrillation%") AND (LOWER(drugName) LIKE "%apixaban%" OR LOWER(tradeNames_list) LIKE "%apixaban%" OR LOWER(syns_list) LIKE "%apixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710506', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710593', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710622', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710651', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710709', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710738', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710767', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710564', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710448', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710390', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710361', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710680', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710535', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710477', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710419', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1178 | Q34 | What are the names of the genes that are targeted by the drug Sitagliptin Phosphate in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Sitagliptin Phosphate targets the gene dipeptidyl peptidase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%sitagliptin phosphate%" OR LOWER(tradeNames_list) LIKE "%sitagliptin phosphate%" OR LOWER(syns_list) LIKE "%sitagliptin phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933072', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933090', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933096', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933102', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933114', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933120', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933126', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933138', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933144', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933150', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933156', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933168', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933174', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933180', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933186', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933192', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933198', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933204', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933210', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933216', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933222', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933234', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933240', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933246', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933252', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933258', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933270', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933276', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933282', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933288', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933294', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933300', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933306', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933228', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933132', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933084', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933060', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933048', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933042', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933264', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933162', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933108', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933078', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933066', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}, {'UUID': 'DrugTargetsIndication121923_text_933054', 'drugName': 'Sitagliptin Phosphate', 'tradeNames_list': "['Janumet Xr', 'Januvia']", 'syns_list': "['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1490 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of choriocarcinoma? | In the context of choriocarcinoma, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%choriocarcinoma%" OR LOWER(efo_term) LIKE "%choriocarcinoma%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057591', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058074', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058235', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058396', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058718', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058879', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059040', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059362', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059523', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059684', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059845', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060167', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060328', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060489', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060650', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060811', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060972', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061133', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061294', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061455', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061616', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061938', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062099', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062260', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062421', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062582', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062904', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063065', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063226', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063387', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063548', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063709', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063870', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064031', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064192', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064353', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064514', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064675', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064836', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064997', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065158', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065319', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065480', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065641', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065802', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065963', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066124', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066285', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066446', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066607', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066768', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067090', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067251', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067412', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067573', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067734', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067895', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068217', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068378', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068539', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068700', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068861', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069022', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069183', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069344', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069505', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069666', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069827', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069988', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070149', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070310', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070471', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070632', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070793', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070954', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071115', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071276', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071437', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071598', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071759', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071920', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072081', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072242', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072403', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066929', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061777', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059201', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057913', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057269', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056947', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056786', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068056', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062743', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060006', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058557', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057752', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057430', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057108', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choriocarcinoma', 'efo_term': 'choriocarcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.427 | Q34 | What are the names of the genes that are targeted by the drug Epoprostenol Sodium in the treatment of pulmonary arterial hypertension? | In the context of pulmonary arterial hypertension, the drug Epoprostenol Sodium targets the gene prostaglandin I2 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%epoprostenol sodium%" OR LOWER(tradeNames_list) LIKE "%epoprostenol sodium%" OR LOWER(syns_list) LIKE "%epoprostenol sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_245984', 'drugName': 'Epoprostenol Sodium', 'tradeNames_list': "['Epoprostenol sodium', 'Flolan', 'Veletri']", 'syns_list': "['Epoprostenol sodium', 'Epoprostenolsodium', 'Prostacyclin sodium saltSodium prostacyclin', 'U-53,217A', 'U-53217A']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245983', 'drugName': 'Epoprostenol Sodium', 'tradeNames_list': "['Epoprostenol sodium', 'Flolan', 'Veletri']", 'syns_list': "['Epoprostenol sodium', 'Epoprostenolsodium', 'Prostacyclin sodium saltSodium prostacyclin', 'U-53,217A', 'U-53217A']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245986', 'drugName': 'Epoprostenol Sodium', 'tradeNames_list': "['Epoprostenol sodium', 'Flolan', 'Veletri']", 'syns_list': "['Epoprostenol sodium', 'Epoprostenolsodium', 'Prostacyclin sodium saltSodium prostacyclin', 'U-53,217A', 'U-53217A']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245985', 'drugName': 'Epoprostenol Sodium', 'tradeNames_list': "['Epoprostenol sodium', 'Flolan', 'Veletri']", 'syns_list': "['Epoprostenol sodium', 'Epoprostenolsodium', 'Prostacyclin sodium saltSodium prostacyclin', 'U-53,217A', 'U-53217A']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.557 | Q34 | What are the names of the genes that are targeted by the drug Riluzole in the treatment of amyotrophic lateral sclerosis? | In the context of amyotrophic lateral sclerosis, the drug Riluzole targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%amyotrophic lateral sclerosis%" OR LOWER(efo_term) LIKE "%amyotrophic lateral sclerosis%") AND (LOWER(drugName) LIKE "%riluzole%" OR LOWER(tradeNames_list) LIKE "%riluzole%" OR LOWER(syns_list) LIKE "%riluzole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_636339', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636408', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636431', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_636454', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_636500', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_636523', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_636546', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_636592', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_636615', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_636638', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636661', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636707', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636730', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636753', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636776', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636799', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636822', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636845', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636868', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636891', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636569', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_636385', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636293', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636247', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636224', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636684', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636477', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_636362', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636316', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_636270', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'syns_list': "['BHV-0223', 'NSC-753433', 'NSC-759823', 'RP 54274', 'RP-54274', 'RiluzoleTiglutik']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.599 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of partial epilepsy? | In the context of partial epilepsy, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%partial epilepsy%" OR LOWER(efo_term) LIKE "%partial epilepsy%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653153', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653246', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653277', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653308', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653370', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653401', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653432', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653494', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653525', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653556', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653587', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653649', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653680', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653711', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653742', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653773', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653804', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653835', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653866', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653897', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653928', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653990', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654021', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654052', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654083', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654114', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654176', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654207', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654238', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654269', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654300', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654331', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654362', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654393', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654424', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654455', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654486', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654517', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654548', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654579', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654610', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654641', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654672', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654703', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654734', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654765', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654796', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654827', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654858', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654889', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654920', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654982', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655013', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655044', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655075', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655106', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655137', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655199', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655230', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655261', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655292', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655323', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655354', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655385', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655416', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655447', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655478', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655509', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655540', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655571', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655602', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655633', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655664', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655695', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655726', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655757', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655788', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655819', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655850', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655881', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655912', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655943', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655974', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656005', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656036', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656067', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_654951', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_653959', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653463', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653215', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653091', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653029', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652998', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_655168', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654145', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_653618', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653339', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653184', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653122', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653060', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1944 | Q34 | What are the names of the genes that are targeted by the drug Enasidenib Mesylate in the treatment of acute myeloid leukemia? | In the context of acute myeloid leukemia, the drug Enasidenib Mesylate targets the gene isocitrate dehydrogenase (NADP(+)) 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute myeloid leukemia%" OR LOWER(efo_term) LIKE "%acute myeloid leukemia%") AND (LOWER(drugName) LIKE "%enasidenib mesylate%" OR LOWER(tradeNames_list) LIKE "%enasidenib mesylate%" OR LOWER(syns_list) LIKE "%enasidenib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192245', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192248', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192249', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192250', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192247', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192243', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192241', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192240', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192251', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192246', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192244', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}, {'UUID': 'DrugTargetsIndication121923_text_1192242', 'drugName': 'Enasidenib Mesylate', 'tradeNames_list': "['Idhifa']", 'syns_list': "['AG-221 mesylate', 'CC-90007', 'Enasidenib mesilate', 'Enasidenib mesylateEnasidenib methanesulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'IDH2', 'approvedName': 'isocitrate dehydrogenase (NADP(+)) 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.370 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_241219', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241465', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241547', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241629', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241793', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241875', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241383', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241055', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240891', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240809', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241711', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241301', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241137', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240973', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1474 | Q34 | What are the names of the genes that are targeted by the drug Avatrombopag Maleate in the treatment of liver disease? | In the context of liver disease, the drug Avatrombopag Maleate targets the gene MPL proto-oncogene, thrombopoietin receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%liver disease%" OR LOWER(efo_term) LIKE "%liver disease%") AND (LOWER(drugName) LIKE "%avatrombopag maleate%" OR LOWER(tradeNames_list) LIKE "%avatrombopag maleate%" OR LOWER(syns_list) LIKE "%avatrombopag maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055941', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'syns_list': "['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Diseases', 'efo_term': 'liver disease', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055939', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'syns_list': "['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Diseases', 'efo_term': 'liver disease', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055945', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'syns_list': "['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Diseases', 'efo_term': 'liver disease', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1055943', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'syns_list': "['Avatrombopag maleate', 'E-5501 MALEATE', 'E5501 MALEATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Liver Diseases', 'efo_term': 'liver disease', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1798 | Q34 | What are the names of the genes that are targeted by the drug Famotidine in the treatment of Peptic ulcer? | In the context of Peptic ulcer, the drug Famotidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%peptic ulcer%" OR LOWER(efo_term) LIKE "%peptic ulcer%") AND (LOWER(drugName) LIKE "%famotidine%" OR LOWER(tradeNames_list) LIKE "%famotidine%" OR LOWER(syns_list) LIKE "%famotidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100332', 'drugName': 'Famotidine', 'tradeNames_list': "['Famotidine', 'Famotidine preservative freeFamotidine preservative free (pharmacy bulk)', 'Fluxid', 'PepcidPepcid ac', 'Pepcid preservative free', 'Pepcid rpd']", 'syns_list': "['Amfamox', 'Fadul', 'Famodil', 'Famosan', 'Famotidine', 'Famoxal', 'GanorGastridin', 'Gastropen', 'L 643341', 'Lecedil', 'MK-208', 'Motiax', 'MucloxNSC-757810', 'Pepcidac', 'Pepdine', 'Pepdul', 'YM-11170']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.627 | Q34 | What are the names of the genes that are targeted by the drug Sorafenib Tosylate in the treatment of papillary renal cell carcinoma? | In the context of papillary renal cell carcinoma, the drug Sorafenib Tosylate targets the gene kinase insert domain receptor, B-Raf proto-oncogene, serine/threonine kinase, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and ret proto-oncogene. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%papillary renal cell carcinoma%" OR LOWER(efo_term) LIKE "%papillary renal cell carcinoma%") AND (LOWER(drugName) LIKE "%sorafenib tosylate%" OR LOWER(tradeNames_list) LIKE "%sorafenib tosylate%" OR LOWER(syns_list) LIKE "%sorafenib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_683538', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683721', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683782', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683843', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683965', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684026', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684087', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684209', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684270', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684331', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684392', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684514', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684575', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684636', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684697', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684758', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684819', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684880', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684941', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685002', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685063', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685185', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685246', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685307', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685368', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685429', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685551', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685612', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685673', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685734', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685795', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685856', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685917', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685124', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684148', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683660', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683416', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683294', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683233', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685490', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684453', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683904', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683599', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683477', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683355', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1460 | Q34 | What are the names of the genes that are targeted by the drug Isotretinoin in the treatment of acne? | In the context of acne, the drug Isotretinoin targets the gene retinoic acid receptor gamma, retinoic acid receptor beta and retinoic acid receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acne%" OR LOWER(efo_term) LIKE "%acne%") AND (LOWER(drugName) LIKE "%isotretinoin%" OR LOWER(tradeNames_list) LIKE "%isotretinoin%" OR LOWER(syns_list) LIKE "%isotretinoin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1054015', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054159', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054207', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054255', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054351', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054399', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054447', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054543', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054591', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054639', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054687', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054783', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054831', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054879', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054927', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1054975', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055023', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055071', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055119', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055167', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055215', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055311', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055359', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055407', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055455', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055263', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1054111', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053919', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053823', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053775', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054495', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054735', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1054303', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1054063', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053967', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1053871', 'drugName': 'Isotretinoin', 'tradeNames_list': "['Absorica', 'Absorica ld', 'Accutane', 'Amnesteem', 'Claravis', 'IsotrexMyorisan', 'Roaccutane', 'Sotret', 'Zenatane']", 'syns_list': "['13 Cis-Retinoic Acid', '13-cis-retinoic acid', 'Isotretinoin', 'NSC-758156PAT-001', 'RO 4-3780', 'RO-4-3780', 'RO-43780', 'Retinoic acid 13-cis-formRetinoic acid, 13-cis-', 'Vitamin a acid, 13-cis']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1600 | Q34 | What are the names of the genes that are targeted by the drug Lisinopril in the treatment of hypertension? | In the context of hypertension, the drug Lisinopril targets the gene angiotensin I converting enzyme. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%lisinopril%" OR LOWER(tradeNames_list) LIKE "%lisinopril%" OR LOWER(syns_list) LIKE "%lisinopril%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091710', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091731', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091738', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091745', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091759', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091766', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091773', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091787', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091794', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091801', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091808', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091822', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091829', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091836', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091843', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091850', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091780', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091724', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091696', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091682', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091675', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091815', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091752', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091717', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091703', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091689', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1893 | Q34 | What are the names of the genes that are targeted by the drug Torsemide in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Torsemide targets the gene solute carrier family 12 member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%torsemide%" OR LOWER(tradeNames_list) LIKE "%torsemide%" OR LOWER(syns_list) LIKE "%torsemide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149091', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1149099', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.229 | Q34 | What are the names of the genes that are targeted by the drug Betamethasone Dipropionate in the treatment of hemorrhoid? | In the context of hemorrhoid, the drug Betamethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhoid%" OR LOWER(efo_term) LIKE "%hemorrhoid%") AND (LOWER(drugName) LIKE "%betamethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%betamethasone dipropionate%" OR LOWER(syns_list) LIKE "%betamethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220896', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220872', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220848', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220836', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220908', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220884', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220860', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1367 | Q34 | What are the names of the genes that are targeted by the drug Acalabrutinib Maleate in the treatment of chronic lymphocytic leukemia? | In the context of chronic lymphocytic leukemia, the drug Acalabrutinib Maleate targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic lymphocytic leukemia%" OR LOWER(efo_term) LIKE "%chronic lymphocytic leukemia%") AND (LOWER(drugName) LIKE "%acalabrutinib maleate%" OR LOWER(tradeNames_list) LIKE "%acalabrutinib maleate%" OR LOWER(syns_list) LIKE "%acalabrutinib maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1024994', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025000', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025002', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025004', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025008', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025010', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025012', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025016', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025018', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025020', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025022', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025026', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025028', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025030', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025032', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025034', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025036', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025038', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025040', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025042', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025044', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025048', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025050', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025052', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025054', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025056', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025060', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025062', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025064', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025066', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025068', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025070', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025072', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025046', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025014', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024998', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024990', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024986', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024984', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025058', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025024', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025006', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024996', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024992', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1024988', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_list': "['Calquence']", 'syns_list': "['Acalabrutinib maleate', 'Acalabrutinib maleate anhydrousCalquence maleate']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1316 | Q34 | What are the names of the genes that are targeted by the drug Riociguat in the treatment of pulmonary hypertension? | In the context of pulmonary hypertension, the drug Riociguat targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary hypertension%" OR LOWER(efo_term) LIKE "%pulmonary hypertension%") AND (LOWER(drugName) LIKE "%riociguat%" OR LOWER(tradeNames_list) LIKE "%riociguat%" OR LOWER(syns_list) LIKE "%riociguat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972939', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972962', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972963', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972974', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972986', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972987', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972998', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973010', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973011', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973022', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973023', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973035', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973046', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973047', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973058', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973059', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973070', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973071', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973082', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973083', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973094', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973106', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973107', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973118', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973119', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973130', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973142', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973143', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973154', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973155', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973166', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973167', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973178', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973179', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973190', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973191', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973202', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973203', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973214', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973215', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973226', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973227', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973238', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973239', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973250', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973251', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973262', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973263', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973274', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973275', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973286', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973298', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973299', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973310', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973311', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973322', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973323', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973335', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973346', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973347', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973358', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973359', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973370', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973371', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973382', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973383', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973394', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973395', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973406', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973407', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973418', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973419', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973430', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973431', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973442', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973443', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973454', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973455', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973466', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973467', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973478', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973479', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973490', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973491', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973502', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973503', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973287', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973095', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972999', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972951', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972927', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972915', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972914', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973334', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973131', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973034', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972975', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972950', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972938', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972926', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1085 | Q34 | What are the names of the genes that are targeted by the drug Testosterone Enanthate in the treatment of hypogonadism? | In the context of hypogonadism, the drug Testosterone Enanthate targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypogonadism%" OR LOWER(efo_term) LIKE "%hypogonadism%") AND (LOWER(drugName) LIKE "%testosterone enanthate%" OR LOWER(tradeNames_list) LIKE "%testosterone enanthate%" OR LOWER(syns_list) LIKE "%testosterone enanthate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921384', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921401', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921402', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921410', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921419', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921420', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921428', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921437', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921438', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921446', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921447', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921456', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921464', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921465', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921473', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921474', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921482', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921483', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921491', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921492', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921500', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921509', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921510', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921518', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921519', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921527', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921536', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921537', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921545', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921546', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921554', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921555', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921563', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921564', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921572', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921573', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921581', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921582', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921590', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921591', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921599', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921600', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921608', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921609', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921617', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921618', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921626', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921627', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921635', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921636', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921644', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921653', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921654', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921662', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921663', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921671', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921672', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921681', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921689', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921690', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921698', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921699', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921707', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921708', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921716', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921717', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921725', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921726', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921734', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921735', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921743', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921744', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921752', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921753', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921761', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921762', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921770', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921771', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921779', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921780', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921788', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921789', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921797', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921798', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921806', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921807', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921645', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921501', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921429', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921393', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921375', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921366', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921365', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921680', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921528', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921455', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921411', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921392', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921383', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921374', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': "['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']", 'syns_list': "['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.67 | Q34 | What are the names of the genes that are targeted by the drug Metoclopramide Hydrochloride in the treatment of kidney failure? | In the context of kidney failure, the drug Metoclopramide Hydrochloride targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 3A and 5-hydroxytryptamine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%kidney failure%" OR LOWER(efo_term) LIKE "%kidney failure%") AND (LOWER(drugName) LIKE "%metoclopramide hydrochloride%" OR LOWER(tradeNames_list) LIKE "%metoclopramide hydrochloride%" OR LOWER(syns_list) LIKE "%metoclopramide hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199705', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199673', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199665', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199689', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199697', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199681', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency', 'efo_term': 'kidney failure', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.25 | Q34 | What are the names of the genes that are targeted by the drug Brexpiprazole in the treatment of psychosis? | In the context of psychosis, the drug Brexpiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psychosis%" OR LOWER(efo_term) LIKE "%psychosis%") AND (LOWER(drugName) LIKE "%brexpiprazole%" OR LOWER(tradeNames_list) LIKE "%brexpiprazole%" OR LOWER(syns_list) LIKE "%brexpiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155832', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155874', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155888', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155902', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155930', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155944', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155958', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155986', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156000', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156014', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156028', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156056', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156070', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156084', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156098', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156112', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156126', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156140', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156154', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156168', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156182', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156210', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156224', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156238', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156252', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156266', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156294', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156308', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156322', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156336', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156350', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156364', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156378', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156392', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156406', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156420', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156434', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156448', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156462', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156476', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156490', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156504', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156518', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156532', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156546', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156560', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156574', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156588', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156602', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156616', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156630', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156658', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156672', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156686', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156700', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156714', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156728', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156756', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156770', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156784', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156798', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156812', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156826', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156840', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156854', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156868', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156882', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156896', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156910', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156924', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156938', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156952', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156966', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156980', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156994', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157008', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157022', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157036', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157050', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157064', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157078', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157092', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157106', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157120', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157134', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157148', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156644', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156196', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155972', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155860', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155804', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155776', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155762', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156742', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156280', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156042', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155916', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155846', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155818', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155790', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.146 | Q34 | What are the names of the genes that are targeted by the drug Lapatinib Ditosylate in the treatment of breast cancer? | In the context of breast cancer, the drug Lapatinib Ditosylate targets the gene epidermal growth factor receptor and erb-b2 receptor tyrosine kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%lapatinib ditosylate%" OR LOWER(tradeNames_list) LIKE "%lapatinib ditosylate%" OR LOWER(syns_list) LIKE "%lapatinib ditosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217409', 'drugName': 'Lapatinib Ditosylate', 'tradeNames_list': "['Tykerb']", 'syns_list': "['GW-572016F', 'GW572016F', 'LapatinibLapatinib ditoluenesulfonate monohydrate', 'Lapatinib ditosylateLapatinib ditosylate anhydrous', 'Lapatinib ditosylate monohydrateLapatinib tosilate', 'Lapatinib tosilate hydrate', 'Tycerb']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217427', 'drugName': 'Lapatinib Ditosylate', 'tradeNames_list': "['Tykerb']", 'syns_list': "['GW-572016F', 'GW572016F', 'LapatinibLapatinib ditoluenesulfonate monohydrate', 'Lapatinib ditosylateLapatinib ditosylate anhydrous', 'Lapatinib ditosylate monohydrateLapatinib tosilate', 'Lapatinib tosilate hydrate', 'Tycerb']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.